HRAS (Protein|Antibody|cDNA Clone|ELISA Kit)

All HRAS reagents are produced in house and quality controlled, including 2 HRAS Antibody, 12 HRAS Gene, 1 HRAS IPKit, 1 HRAS Lysate, 1 HRAS Protein, 1 HRAS qPCR. All HRAS reagents are ready to use.

Recombinant HRAS proteins are expressed by Baculovirus-Insect Cells with fusion tags as C-His.

HRASantibodies are validated with different applications, which are ELISA, WB, IP.

HRAScDNA clones are full length sequence confirmed and expression validated. There are 13 kinds of tags for each HRAS of different species, especially GFP tag, OFP tag, FLAG tag and so on. There are three kinds of vectors for choice, cloning vector, expression vector and lentivrial expression vector.

HRAS Protein (1)


HRAS Protein, Human, Recombinant (His Tag)


Expression host: Baculovirus-Insect Cells

Human HRAS Protein 9949

HRAS Antibody (2)

Application Clonality

Anti-HRAS Antibody


Application: ELISA

Clonality: PAb

Anti-HRAS Antibody


Application: WB,ELISA,IP

Clonality: PAb

Human HRAS Immunoprecipitation(IP) 6034

HRAS cDNA Clone (12)


HRAS qPCR Primer (1)

HRAS IP Kit (1)

HRAS Lysate (1)

HRas, also known as HRAS, belongs to the small GTPase superfamily, Ras family and is widely expressed. It functions in signal transduction pathways. HRas can bind GTP and GDP, and they have intrinsic GTPase activity. It undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Defects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS). FCSS is arare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities, tumor predisposition, skin and musculoskeletal abnormalities. Defects in HRAS also can cause congenital myopathy with excess of muscle spindles. HRAS deficiency may be a cause of susceptibility to Hurthle cell thyroid carcinoma. It has been shown that defects in HRAS can cause susceptibility to bladder cancer which is a malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. Defects in HRAS are the cause of oral squamous cell carcinoma.

Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy